Company Overview

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to activate the innate immune system for the treatment of cancer and infectious diseases. The company operates within the biotechnology and immuno-oncology sectors, with research centered on systemic anti-tumor immune activation using proprietary bacterial-derived therapies. Its primary product platform is based on “Killed but Metabolically Active” (KBMA) technology, which uses engineered and attenuated Gram-negative bacteria intended to stimulate multiple innate immune pathways simultaneously.

The company’s lead product candidate, Decoy20, is being evaluated as an intravenous immunotherapy designed to trigger broad immune responses through activation of toll-like receptors and other immune signaling mechanisms. Indaptus primarily targets oncology indications, including solid tumors that may be resistant to checkpoint inhibitors or other immunotherapies. The company was founded in 2010 and later became publicly traded on the Nasdaq Capital Market under the ticker INDP. Its strategic positioning is based on combining broad innate immune activation with potentially lower toxicity than live bacterial therapies, differentiating it from traditional cytokine-based or single-target immunotherapy approaches.

Business Operations

Indaptus operates primarily through a single biotechnology research and development business focused on immunotherapeutic product development. The company does not currently generate material commercial revenue and instead finances operations primarily through public equity offerings and related capital market activities disclosed in SEC filings. Research activities are concentrated on advancing Decoy20 through clinical development, including dose-escalation studies and combination therapy evaluation. The company’s operating model is centered on preclinical research, clinical trial execution, regulatory engagement, and intellectual property development.

The company’s proprietary KBMA platform represents its principal technological asset. This platform involves engineering bacteria that are unable to replicate but retain metabolic activity capable of stimulating immune pathways. Indaptus has also pursued collaborations with contract research organizations, manufacturers, and academic institutions supporting clinical and translational research. Public disclosures indicate the company maintains intellectual property related to bacterial engineering and immunotherapy applications, although no major revenue-generating subsidiaries or large-scale joint ventures have been publicly identified in available filings.

Strategic Position & Investments

Indaptus’ strategic direction is focused on advancing innate immune system-based therapeutics as potential complements or alternatives to existing cancer immunotherapies. The company’s growth initiatives center on clinical development of Decoy20, expansion into combination treatment approaches with checkpoint inhibitors, and exploration of infectious disease applications. Public company disclosures and investor materials indicate management believes multi-pathway immune activation could address limitations associated with therapies targeting single immune mechanisms.

The company’s investments are concentrated primarily in research and development activities, clinical trial infrastructure, manufacturing capabilities, and intellectual property protection. Indaptus has emphasized development of scalable manufacturing processes for its bacterial-derived therapeutics and has continued to invest in regulatory and clinical advancement. Based on available public information, the company remains a development-stage biotechnology enterprise without significant diversification into unrelated sectors or ownership of large portfolio companies. Data regarding additional undisclosed strategic investments or material acquisition activity is inconclusive based on available public sources.

Geographic Footprint

Indaptus Therapeutics is headquartered in the United States, with principal operations based in New York. Its activities are primarily concentrated in the U.S. biotechnology and clinical research ecosystem, including relationships with domestic clinical trial sites, contract manufacturers, and regulatory agencies such as the U.S. Food and Drug Administration. The company’s securities are publicly traded on the Nasdaq Capital Market, providing access to U.S. capital markets.

Although Indaptus does not currently report extensive international commercial operations, its therapeutic development strategy has relevance to global oncology and infectious disease markets. Clinical development activities may involve internationally recognized research partners and service providers commonly used within the biotechnology industry. Public filings do not currently indicate substantial direct operational infrastructure across multiple continents, and data regarding major international subsidiaries or foreign operating hubs is inconclusive based on available public sources.

Leadership & Governance

Indaptus Therapeutics is led by executives with backgrounds in biotechnology, pharmaceuticals, immunology, and clinical development. Leadership has emphasized advancing novel innate immune therapies through disciplined clinical development and regulatory execution. Corporate governance is overseen by a board of directors and executive management team consistent with publicly traded biotechnology company standards outlined in SEC filings and Nasdaq governance requirements.

Key executives include:

• Jeffrey Meckler – Chief Executive Officer
• Roger Waltzman, M.D., M.B.A. – Chief Medical Officer
• Mark Strobeck, Ph.D. – President and Chief Scientific Officer
• Nina Bhattacharya – Chief Financial Officer

Management’s strategic vision has focused on developing differentiated immunotherapies capable of activating broad immune responses while maintaining manageable safety profiles. Public communications and investor presentations indicate leadership prioritizes clinical validation of the company’s KBMA platform and expansion of therapeutic applications in oncology and infectious disease settings.